Founded with a mission to revolutionize the diagnosis and treatment of neurological disorders, NVector specializes in gene therapy technology. The company's core focus is on developing diagnostic platforms for conditions such as amyotrophic lateral sclerosis (ALS) and traumatic brain injuries. Their innovative biomarker-based tests aid in the early diagnosis and effective management of these disorders. Additionally, NVector's advanced Adeno-Associated Virus (AAV) platform enhances targeted delivery to brain glia and neuron cells, ensuring better distribution throughout the spinal cord and brain from a single injection.

NVector has garnered attention for its cutting-edge contributions to the field of central nervous system (CNS) disorders. The company collaborates with leading researchers and institutions to accelerate the development of breakthrough treatments. Notable investors and affiliations include prominent figures in the biotech and medical research communities. NVector's achievements in biomarker testing and gene therapy have significantly impacted the landscape of neurological disorder management, offering new hope for conditions previously deemed untreatable.